From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
Industry News
News from pharmaceutical companies and other related healthcare organizations
Crinetics new drug candidate for acromegaly Paltusotine awarded Orphan Drug Designation
July 30, 2020
From a Crinetics Pharmaceutical press release: Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced that the
More information on Recordati’s new Cushing’s drug Isturisa
July 30, 2020
In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology. “The exciting data, published today, underscore the efficacy and safety
More news on Isturisa for Cushing’s
June 10, 2020
In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States, announced the full availability of Isturisa® for the treatment of adult
From Endocrine Web: New Oral Acromegaly Treatment Has No Needles Required
May 14, 2020
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
A new drug for Cushing’s: Learn more
April 22, 2020
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
Exciting news for acromegaly and NET’s from Crinetics Pharmaceuticals!
April 9, 2020
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
News on Signifor, Signifor LAR, and newly approved Cushing’s drug ISTURISA
April 8, 2020
Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products treat pituitary diseases. SIGNIFOR LAR, a “2nd generation” somatostatin analog given
Questions about access to therapies, financial assistance?
March 30, 2020
If you are currently taking, or are about to start taking Lanreotide (Somatuline Depot) injections, this website from Ipsen offers a wealth of information about patient access to therapies. IPSEN CARES serves as a central